



SIMRAN FARMS LIMITED

CIN: L01222MP1984PLC002627

Reg. Office: 1-B, Vikas Rekha Complex, Tower Square,
Khatiwala Tank, Indore (M.P.)- 452001

Tel No.: 0731-4255900; Fax: 0731-4255949

Email- compliance@simranfarms.com

Website: www.simranfarms.com

SFL/BSE/16/2025-26 Online filing at www.listing.bseindia.com Date: 13th August, 2025

To
The Secretary,
Corporate Relationship Department
BSE Limited,
Phiroze Jeejeebhoy Towers, 'A' wing
Dalal Street, Fort
Mumbai – 400021

Subject: Outcome of the Board Meeting held on Wednesday, 13th August, 2025 under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).

Reference: SIMRAN FARMS LIMITED (BSE Scrip Code: 519566; ISIN: INE354D01017)

Dear Sir/Madam,

In continuation to our earlier intimation of Board Meeting filed as on 5th August, 2025 and in terms of the provisions of Regulation 30 (read with Part A of Schedule III) of the SEBI Listing Regulations, this is to inform you that the Board of Directors of the company, in their meeting held today i.e. Wednesday, 13th August, 2025, has inter alia, considered & approved, the following proposals:-

1. Standalone as well as Consolidated Un-Audited Financial Results of the Company for the quarter ended 30th June, 2025 along with the Limited Review Reports thereon. (**Copy of financial results enclosed herewith**).
2. Based on recommendation of the Audit Committee, appointment of Ramesh Chandra Bagdi & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company for period of five consecutive years commencing from FY 2025-2026 till FY 2029-2030 and fix their remuneration, subject to approval of the shareholders of the Company at the ensuing 38th Annual General Meeting of the company

Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 with reference to appointment of Secretarial Auditor is being submitted separately in pdf and xbrl form within prescribed time.

3. Approval of Board's Report on the Operation of the Company along with required annexure and Corporate Governance Report & Management Discussion and Analysis Report for the year ended 31st March, 2025.
4. Convening of 38th Annual General Meeting (AGM) on Thursday, 25th day of September, 2025 at 11.30 A.M. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).

5. Mr. Kawaljeet Singh Bhatia (00401827) Whole Time Director of the Company has demitted his office as Whole Time Director of the Company with effect from the close of business hours on 13th August, 2025. However he will continue on the Board of Directors of the Company as Non-Executive, Non-Independent Director and shall be liable to retire by rotation.

Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 with reference to Change in designation of aforesaid Director is being submitted separately in pdf and xbrl form within prescribed time.

6. Other routine businesses with the permission of chair.

Further, copy of aforesaid Un-Audited Financial Results of the Company shall also be submitted in XBRL (Integrated Filing Financial) mode within prescribed time limit.

The aforesaid Un-Audited Financial Results of the Company shall also be uploaded on the Company's website i.e. www.simranfarms.com and on the website of the Stock Exchange i.e. at www.bseindia.com. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers within prescribed time limit.

The Meeting of the Board of Directors commenced at 3.00 P.M. and concluded at 6.45 P.M.

The above information will also be available on the website of Company at www.simranfarms.com.

You are requested to take on record the above said information for your reference and records.

Thanking You,

Yours faithfully

FOR, SIMRAN FARMS LIMITED

CS TANU PARMAR
CS & COMPLIANCE OFFICER
M. NO. A34769

Encl.: Un-audited Standalone and Consolidated Financial Results along with limited review report for quarter ended on 30th June, 2025.

SIMRAN FARMS LIMITED

(CIN: L01222MP1984PLC002627)


Regd. Office: 1-B, Vikas Rekha Complex, Khatiwala Tank, Tower Square, Indore (M.P.) 452001

Phone: 0731-4255900, Fax: 0731-4255949; Web: www.simranfarms.com, Email: compliance@simranfarms.com

UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs. In Lakhs except EPS)

S. No.	Particulars	STANDALONE				CONSOLIDATED			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
		Reviewed	Unaudited	Reviewed	Audited	Reviewed	Unaudited	Reviewed	Audited
			(Refer note 7)			(Refer note 7)			
I	Income from Operations	20494.47	23823.98	17640.99	83440.93	20494.47	23823.98	17640.99	83440.93
II	Other Income	51.63	45.68	55.90	183.28	51.63	45.68	55.90	183.28
III	Total Revenue (I+II)	20546.10	23869.66	17696.89	83624.21	20546.10	23869.66	17696.89	83624.21
IV	Expenses								
	(a)Consumption of raw materials consumed	17477.91	20688.78	14003.97	70377.71	17477.91	20688.78	14003.97	70377.71
	(b)Changes in inventories of finished goods								
	(c)Employees benefits expenses	599.45	625.43	461.92	2151.36	606.35	632.33	468.82	2178.96
	(d)Depreciation	42.15	46.03	43.86	180.03	43.42	47.69	45.52	186.65
	(e)Finance Cost	71.59	51.83	18.72	106.50	71.59	51.83	18.72	106.59
	(f)Other expenses	2255.28	2952.33	1948.02	10012.73	2243.27	2940.35	1935.78	9964.58
	Total Expenses (IV)	20446.38	24364.40	16476.49	82828.33	20442.54	24360.98	16472.81	82814.49
V	Profit/(Loss) from Operations before exceptional and tax (III-IV)	99.72	(494.74)	1220.40	795.88	103.56	(491.32)	1224.08	809.72
VI	Exceptional items / Mat adjustment	0.00	0.00	0.00	0.00	0.00	0.00		0.00
VII	Profit/(Loss) before tax (V-VI)	99.72	(494.74)	1220.40	795.88	103.56	(491.32)	1224.08	809.72
VIII	Tax expense								
	i) Current tax	28.92	(143.53)	341.02	224.98	30.14	(142.21)	342.27	229.90
	ii) Deferred tax	(0.66)	(26.23)	9.36	(8.60)	(2.75)	(28.19)	9.46	(9.79)
	iii) MAT credit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Total Tax Expenses (VIII)	28.26	(169.76)	350.38	216.38	27.39	(170.40)	351.73	220.11
IX	Net Profit/ (Loss) for the period from continuing operations (VII-VIII)	71.46	(324.98)	870.02	579.50	76.17	(320.92)	872.35	589.61
X	Profit/ (Loss) for the period from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expenses from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XII	Net Profit/ (Loss) for the period from discontinuing operations (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Net Profit/ (Loss) for the period (IX+XII)	71.46	(324.98)	870.02	579.50	76.17	(320.92)	872.35	589.61
XIV	Other comprehensive income								
	Item that will not be reclassified to profit and loss i.e. Remeasurement of defined benefit plans.	0.00	(27.14)	0.00	(27.14)	0.00	(27.14)	0.00	(27.14)
	Less:- Income Tax relating to Item that will not be reclassified to profit and loss i.e. Remeasurement of defined benefit plans.	0.00	(7.55)	0.00	(7.55)	0.00	(7.55)	0.00	(7.55)
	Other Comprehensive Income (XIV)	0.00	(19.59)	0.00	(19.59)	0.00	(19.59)	0.00	(19.59)
XV	Total comprehensive income for the period (XIII+XIV)	71.46	(344.57)	870.02	559.91	76.17	(340.51)	872.35	570.02
XVI	Non controlling interest	0.00	0.00	0.00	0.00	0.81	0.44	0.40	1.75
XVII	Total comprehensive income for the period (XV-XVI)	71.46	(344.57)	870.02	559.91	75.36	(340.95)	871.95	568.27
XVIII	Paid up Equity Share Capital (Face Value of the Shares of Rs. 10/- each)	379.17	379.17	379.17	379.17	379.17	379.17	379.17	379.17
XIX	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year				3217.27				3300.59
XX	Earnings Per Share (EPS) (Face Value of Rs. 10/- each)								
	Basic	1.88	(8.57)	22.95	15.28	2.01	(8.46)	23.00	15.55
	Diluted	1.63	(8.57)	22.95	14.86	1.73	(8.46)	23.00	14.45



Note:

1. The above unaudited results for the Quarter ended June 30, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 13/08/2024. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. The above consolidated financial statement includes the financial figures of subsidiary Company i.e. Puregene Biotech Limited.
3. The Company has been primarily engaged in Poultry Breeding & Farming activities only. As such there is no identifiable operating segment, hence there is nothing to disclose under IND AS - 108 'Operating Segment'.
4. The aforesaid unaudited financial results will be uploaded on the Company's website www.simranfarms.com and will also be available on the website of the BSE Limited www.bseindia.com for the benefit of shareholders and investors.
5. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
6. Previous year figures are regrouped/reclassified to conform the current year's presentation.
7. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter which were subjected to limited review.

Place : INDORE
Date : 13th August, 2025



For, Simran Farms Limited

H.S. Bhatia


H.S. Bhatia
Managing Director
DIN- 00509426

Independent Auditor's Review Report on Standalone Unaudited Quarterly and year to date Financial Results of the Company pursuant to regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

**TO
THE BOARD OF DIRECTORS OF
SIMRAN FARMS LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SIMRAN FARMS LIMITED** (the "Company"), for the quarter ended June 30th, 2025 and year to date results for the period 1st April 2025 to 30th June 2025 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khandelwal Kakani & Co.
Chartered Accountants
(Firm's Registration No. 001311C)



CA V.K. Khandelwal
Partner

Membership No. 070546
UDIN: 25070546BMJLKL5994

Place: Indore
Date: August 13th, 2025

Branches : • INDORE • RATLAM • MANDSAUR • BHOPAL • MUMBAI

Independent Auditor's Review Report on Consolidated Unaudited Quarterly and year to date Financial Results of the Company pursuant to regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

**TO
THE BOARD OF DIRECTORS OF
SIMRAN FARMS LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SIMRAN FARMS LIMITED** (the "Company" or "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group"), for the quarter ended June 30th, 2025 and year to date results for the period 1st April 2025 to 30th June 2025 (the "Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

S.No.	Name of the Company	CIN No.
1	Simran Farms Limited (Holding Company)	L01222MP1984PLC002627
2	Puregene Biotech Limited (Subsidiary Company)	U01222MP1999PLC013303




Branches : • INDORE • RATLAM • MANDSAUR • BHOPAL • MUMBAI

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results includes the interim financial results of one subsidiary which has not been reviewed by its auditors, whose interim financial results reflect total revenue of Rs. 13.5 Lakhs and Rs. 13.5 lakhs, total net profit after tax of Rs. 4.71 Lakhs and Rs. 4.71 Lakhs and total comprehensive income Rs. 4.71 Lakhs and Rs. 4.71 Lakhs for the quarter ended June 30th 2025 and for the period from 1st April 2025 to 30th June 2025, respectively, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our opinion on the Statement is not modified in respect of the above matter.

For Khandelwal Kakani & Co.
Chartered Accountants
(Firm's Registration No. 001311C)



CA V.K. Khandelwal
Partner

Membership No. 070546
UDIN: 25070546BMJLKM3882

Place: Indore
Date: August 13th, 2025